Multiple myeloma requires long-term maintenance therapy, which aims to effectively maintain the depth and prolong the duration of remission, and is of great significance in slowing down the progression and recurrence of the disease. Multiple myeloma is a malignant disease of hematological system, and the clinic mainly adopts induction chemotherapy or hematopoietic stem cell transplantation as the first choice of treatment, and long-term maintenance therapy is also needed after complete remission, which is commonly used as single-drug or multi-drug combination therapy with drugs such as interferon, glucocorticosteroid, lenalidomide, bortezomib and so on. Maintenance therapy, i.e., long-term treatment, should ensure that it is easy to administer, has fewer adverse effects, and prolongs the patient’s survival. Maintenance therapy is a long-term process, and all of the above medications have certain adverse reactions, should be under the guidance of the doctor to choose drug therapy, not self-medication.